oral COVID-19 is a Vaxart, Inc. program in COVID-19 prevention. Its next catalyst is a Readout in Q2 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: COVID-19 prevention. Sponsor: Vaxart, Inc. (VXRT). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for oral COVID-19 is a Readout in Q2 2027.
No FDA decision for oral COVID-19 is in our archive yet.
In our records oral COVID-19 is under review or in development for COVID-19 prevention.
Vaxart, Inc. (VXRT).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.